VOR Company Profile and Key Details

VOR has shown mixed momentum, gaining 24.38% over the past week and -39.31% over the past quarter, though year-to-date performance is up 34.56%. Short-term trend indicators are bullishly aligned (SMA20 16.8%, SMA50 14.23%, SMA200 -29.37%). The stock’s 14-day RSI is 62.31 (firm momentum), while the ATR of 1.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -75.84% below its high and over 506.41% above its low. Average 10-day trading volume of 1.45 million shares is slightly above the 3-month average of 1.06 million, indicating heightened recent market interest.

Vor Biopharma Inc. has 126.68 million shares outstanding. The public float is 52.66 million shares, elevated short interest at 41.28% of float. This equals 19.78 million shares. The short ratio is 4.26 days. Institutional investors hold 72.39% of the float. Insiders own 4.29%. RA CAPITAL MANAGEMENT, L.P. holds 2.40 million shares, 5AM Ventures VI, L.P. has 1.77 million shares and PARMAR KUSH has 1.77 million shares. Over the past six months, insider transactions show net selling. They sold 1.81 million shares across 11 transactions.

Vor Biopharma Inc. (NASDAQ:VOR) closed at $14.85 USD, losing -$0.09 (-0.60%) from the previous close of $14.94. The stock is currently mid-range between its 52-week high and low $5.80 and $65.80. With a market capitalization of about $101.78 million, Vor Biopharma Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.73). Key stats such as the average daily volume over the past year has been around 1.04 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Vor Biopharma Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jean-Paul Kress, the company employs approximately 159 people and listed since February 05, 2021. Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer.

Vor Biopharma Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $39.86. This means the shares are trading below this model’s fair value.

Vor Biopharma Inc. generated EPS of -$386.85 over the past year. Five-year average earnings growth is -38.02%. Wall Street analysts project EPS growth of 42.64% annually over the next five years. The latest quarter delivered EPS of -$5.11. The next quarter is forecast at -$1.02. Next year's EPS is expected at $2.24. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 8 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $64.00 to $0.40. The high target offers 330.98% upside. The low target suggests -97.31% downside. The mean target is $27.96. This offers 88.28% upside. Vor Biopharma Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 13, 2026, missed forecasts by 581.33%. The prior quarter beat by -7296.49%. Over the last six quarters, Apple has recorded several small beats. These include 29.41% in March 20, 2025.

Vor Biopharma Inc. (NASDAQ:VOR) shares are up 34.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Vor Biopharma Inc. trading at a premium to the broader market with a P/E of -0.03. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $22.88, suggesting 54.07% upside. Our AI forecast model points to short-term weakness (-2.9% over two weeks), a medium-term rise (582.15% over three months), and a longer-term loss (-85.39% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Vor Biopharma Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.9%, with price expected at $14.42 by July 06, 2026, within a range of $13.31 to $15.52 3-Month Outlook: Projected rise of 582.15%, reaching $101.30 by September 18, 2026, with a range of $100.08 to $103.12. 1-Year Outlook: Projected loss of -85.39%, with price at $2.17 by June 22, 2027, within a range of $0.00 to $0.00.

Vor Biopharma Inc. trades at a P/E ratio of -0.03, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.04 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.69, also above market averages.